<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02506530</url>
  </required_header>
  <id_info>
    <org_study_id>14 7425 15</org_study_id>
    <nct_id>NCT02506530</nct_id>
  </id_info>
  <brief_title>Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema, During an Intensive Decongestive Treatment</brief_title>
  <acronym>ELOCS</acronym>
  <official_title>Contribution of an Endermologie LPG Cellu M6 Treatment in the Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema, During an Intensive Decongestive Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LPG SYSTEMS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the benefit of LPG Cellu M6 in addition of intensive decongestive
      treatment in reducing secondary lymphoedema in breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the study is to assess the proportion of successfully treated patients
      (success rate).

      That is to say patients having a reduction of excess arm volume ≥ 30% after 5 days of three
      types of treatment for secondary lymphoedema :

      Group 1: standard intensive decongestive therapy for 5 days (bandages + manual lymphatic
      drainage).

      Group 2: standard intensive decongestive therapy (bandages + manual lymphatic drainage) +
      Cellu M6 for 5 days Group 3: Bandages + Cellu M6 for 5 days

      Symptomatic treatment of lymphoedema reference is intensive decongestive therapy including
      manual lymphatic drainage, compression of multicomponent bandaging, therapeutic exercise and
      skin care (HAS 2012 ISL International Society of Lymphology, 2013).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients successfully treated (reduction of the excessive volume in the arm&gt;30%)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of the excessive volume in the arm since hospitalization</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess adverse effects</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>cost effectiveness analysis of treatments</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Lymphedema</condition>
  <arm_group>
    <arm_group_label>intensive decongestive treatment (IDT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive an intensive decongestive treatment for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDT + Cellu M6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive an intensive decongestive treatment + Cellu M6 for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cellu M6 + bandages</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive an bandages + Cellu M6 for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intensive decongestive treatment</intervention_name>
    <description>intensive decongestive treatment</description>
    <arm_group_label>intensive decongestive treatment (IDT)</arm_group_label>
    <arm_group_label>IDT + Cellu M6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cellu M6</intervention_name>
    <description>Use of Cellu M6</description>
    <arm_group_label>IDT + Cellu M6</arm_group_label>
    <arm_group_label>Cellu M6 + bandages</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from a lymphoedema consequence of a breast cancer of grades 2 or 3
             (ISL)

          -  Patients suffering from Lymphoedema for 6 months or more

          -  Patients with a difference between arms &gt;10%

          -  Patients who had ever had an axillary node dissection

          -  Patients hospitalized for intensive standard treatment.

        Exclusion Criteria:

          -  Primary lymphoedema

          -  Venous insufficiency of the upper members

          -  severe arterial obstruction

          -  obliterating arteritis of the upper limbs

          -  Bilateral lymphoedema

          -  Breast cancer recurrence

          -  Another cancer in treatment

          -  Decompensated heart failure

          -  Pacemaker

          -  acute infection

          -  Deep venous thrombosis

          -  Skin atrophy of the upper member

          -  Bullous dermatosis

          -  Acute dermatitis with epidermitis or dermatitis-hypodermitis

          -  Infected wound

          -  Inflammatory scar or consequence of a recent surgery (&lt;1 month)

          -  Presence of osteosynthesis equipment under the skin with an external part in the upper
             member to treat

          -  Hyperalgesia of the shoulder

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie MALLOIZEL-DELAUNAY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie MALLOIZEL-DELAUNAY, MD</last_name>
    <phone>05 61 32 30 33</phone>
    <phone_ext>+33</phone_ext>
    <email>malloizel-delaunay.j@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marianne LESCOUZERES</last_name>
    <phone>05 61 77 72 08</phone>
    <phone_ext>+33</phone_ext>
    <email>lescouzeres.m@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MALLOIZEL DELAUNAY Julie</name>
      <address>
        <city>Toulouse</city>
        <state>Midi Pyrenees</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie MALLOIZEL DELAUNAY, MD</last_name>
      <phone>05 61 32 30 33</phone>
      <phone_ext>+33</phone_ext>
      <email>malloizel-delaunay.j@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Julie MALLOIZEL DELAUNAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte VAYSSE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Lawenda BD, Mondry TE, Johnstone PA. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin. 2009 Jan-Feb;59(1):8-24. doi: 10.3322/caac.20001. Review.</citation>
    <PMID>19147865</PMID>
  </reference>
  <reference>
    <citation>Kärki A, Anttila H, Tasmuth T, Rautakorpi UM. Lymphoedema therapy in breast cancer patients: a systematic review on effectiveness and a survey of current practices and costs in Finland. Acta Oncol. 2009;48(6):850-9. doi: 10.1080/02841860902755251. Review.</citation>
    <PMID>19235573</PMID>
  </reference>
  <reference>
    <citation>Mayrovitz HN. The standard of care for lymphedema: current concepts and physiological considerations. Lymphat Res Biol. 2009;7(2):101-8. doi: 10.1089/lrb.2009.0006.</citation>
    <PMID>19522678</PMID>
  </reference>
  <reference>
    <citation>Vignes S, Porcher R, Arrault M, Dupuy A. Long-term management of breast cancer-related lymphedema after intensive decongestive physiotherapy. Breast Cancer Res Treat. 2007 Mar;101(3):285-90. Epub 2006 Jul 7.</citation>
    <PMID>16826318</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2015</study_first_submitted>
  <study_first_submitted_qc>July 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <last_update_submitted>November 12, 2015</last_update_submitted>
  <last_update_submitted_qc>November 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lymphedema</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
    <mesh_term>Breast Cancer Lymphedema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

